ST6GAL2
Beta-galactoside alpha-2,6-sialyltransferase 2
Protein Summary
Transfers sialic acid from the donor of substrate CMP-sialic acid to galactose containing acceptor substrates. Has alpha-2,6-sialyltransferase activity toward oligosaccharides that have the Gal-beta-1,4-GlcNAc sequence at the non-reducing end of their carbohydrate groups, but it has weak or no activities toward glycoproteins and glycolipids. This locus encodes a sialyltransferase. The encoded type II transmembrane protein catalyzes the transfer of sialic acid from CMP to an oligosaccharide substrate. Polymorphisms at this locus may be associated with variations in risperidone response in schizophrenic patients. Alternatively spliced transcript variants have been described. [provided by RefSeq, Jan 2012]
- ENST00000361686
- ENSP00000355273
- ENSG00000144057
- ENST00000409087
- ENSP00000387332
- ENST00000409382
- ENSP00000386942
- KIAA1877
- SIAT2
- SIAT2
- ST6GalII
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
gene perturbation | 0.9 | ||
microRNA | 0.81 | ||
cell type or tissue | 0.68 | ||
phenotype | 0.59 | ||
transcription factor | 0.55 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 42.3 (req: < 5)
Gene RIFs: 6 (req: <= 3)
Antibodies: 80 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 42.3 (req: >= 5)
Gene RIFs: 6 (req: > 3)
Antibodies: 80 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 3
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0